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Ether lipids are an emerging class of lipids which have so far not been investigated and understood in
every detail. They have important roles as membrane components of e.g. lens, brain and testis, and as
mediators such as platelet-activating factor. The metabolic enzymes for biosynthesis and degradation
have been investigated to some extent. As most involved enzymes are integral membrane proteins they
are tricky to handle in biochemical protocols. The sequence of some ether lipid metabolising enzymes
has only recently been reported and other sequences still remain obscure. Deﬁned enzymes without
assigned sequence are known as orphan enzymes. One of these enzymes with uncharacterised sequence
is plasmanylethanolamine desaturase, a key enzyme for the biosynthesis of one of the most abundant
phospholipids in our body, the plasmalogens. This review aims to brieﬂy summarise known functions of
ether lipids, give an overview on their metabolism including the most prominent members, platelet-
activating factor and the plasmalogens. A special focus is set on the description of orphan enzymes in
ether lipid metabolism and on the successful strategies how four previous orphans have recently been
assigned a sequence. Only one of these four was characterised by classical protein puriﬁcation and
sequencing, whereas the other three required alternative strategies such as bioinformatic candidate gene
selection and recombinant expression or development of an inhibitor and multidimensional metabolic
proﬁling.
 2012 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Ether lipids
1.1. Chemical nature and function of ether lipids
Ether lipids (alkyl and alkenyl glycerols) have an alkyl chain of
mostly 16 or 18 carbon atoms linked to the sn-1 position of the
backbone glycerol by an ether bond. This ether bond, in contrast to
the ester bond of the better described acyl lipids, provides this lipid
class with a higher metabolic stability. Ether lipids are present in
organisms ranging from bacteria, protozoa, fungi, higher plants to
mammals including humans [1e3]. Most prevalent are these ether
bonded side chains in phospholipids, here again saturated alkyl
side chains are predominantly found in phosphatidylcholines and
single unsaturated alkyl side chains (alk-10-enyl) in phosphatidyl-
ethanolamines [4]. Alk-10-enyl phospholipids have a vinyl ether
bond and are termed plasmalogens. It has been shown that the
amount of ether lipids in human and animal tumours is higher in
neoplastic than in healthy cells [5,6]. Other studies have conﬁrmed
the increased presence of ether lipids in cancerous cells [7e10].fax: þ43 512 9003 73330.
erner).
der CC BY-NC-ND license.Encouraged by these ﬁndings, there were efforts trying to establish
ether lipids as tumour markers in medical cancer diagnostics [11],
however, as follow-up investigations found unaltered or even
decreased amounts of ether lipids this path had to be abandoned
[12,13].
Ether lipids in the diet are thought to have general beneﬁcial
effects on health. Shark oil which is especially rich in these lipids is
used for wound healing and against gastric ulcers, colon inﬂam-
mation and arthritis [14]. Ether lipids have been reported to be
immunostimulatory by activation of macrophages and to confer an
anti-angiogenic effect [15]. Their activity spectrum also includes
antibacterial [16] and antifungal [17] properties and they can
increase permeability of the blood brain barrier thereby enabling
delivery of drugs to the brain [18e20]. Another study reported an
increase in sperm motility in pigs and elevated fertility after
treatment with these molecules [21]. In MadineDarby canine
kidney cells, alkylglycerols have been shown to inhibit protein
kinase C (PKC) and thereby mediate cell-density dependence of
proliferation in vitro [22].
A well-studied alkylglycerol is the platelet-activating factor
(PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, (18) in
Fig. 1). It is involved in physiological processes such as e.g.
inﬂammation, reproduction and blood pressure regulation. It has
Fig. 1. Ether lipid metabolism including biosynthesis and degradation of PAF and plasmalogens. Reactions catalysed by orphan enzymes (i.e. enzymes with unknown sequence) are
shown in black circles with white lettering and enzymes with recent sequence assignments in grey circles with white lettering. R, carbon side chain of R1, mostly 15 or 17 atoms
(¼acyl); R2, 14 or 16 atoms (¼alkyl); R3, at least 15 atoms, single- or poly-unsaturated (¼acyl). For a description of the enzymatic reactions (capital letters) and the metabolites
(Arabic numerals, underlined, italic) see text. ENZYMES (A) glycerone-phosphate O-acyltransferase (E.C. 2.3.1.42), (A2) phospholipase A2 (E.C. 3.1.1.4), (B) alkylglycerone-phosphate
synthase (E.C. 2.5.1.26), (C) acylglycerone-phosphate reductase (E.C. 1.1.1.101), (D) alkylglycerol kinase (E.C. 2.7.1.93), (E) alkylglycerolphosphate 2-O-acyltransferase (E.C. 2.3.1.-), (F)
phosphatidate phosphatase (E.C. 3.1.3.4), (G) ethanolamine-phosphotransferase (E.C. 2.7.8.1), (H) diacylglycerol cholinephosphotransferase (E.C. 2.7.8.2), (I) plasmanylethanolamine
desaturase (E.C. 1.14.99.19), (J) a not further characterised transferase (E.C. 2.6.-.-), (K) phospholipase C (E.C. 3.1.4.3), (L) 1-alkylglycerophosphocholine O-acyltransferase (E.C.
2.7.8.22), (M) alkenylglycerophosphocholine hydrolase (E.C. 3.3.2.2), (N) alkenylglycerophosphoethanolamine hydrolase (E.C. 3.3.2.5), (O) 1-O-alkyl-2-acetylglycerophosphocholine
esterase (E.C. 3.1.1.47), (P) alkylglycerol monooxygenase (E.C. 1.14.16.5), (Q) long-chain-aldehyde dehydrogenase (E.C. 1.2.1.48), (R) 1-alkenylglycerophosphocholine O-acyltransferase
(E.C. 2.3.1.104), (S) 1-alkylglycerophosphocholine O-acyltransferase (E.C. 2.3.1.63), (T) 1-alkenylglycerophosphoethanolamine O-acyltransferase (E.C. 2.3.1.121), (U) alkylglycer-
ophosphate 2-O-acetyltransferase (E.C. 2.3.1.105), (V) alkylacetylglycerophosphatase (E.C. 3.1.3.59), (W) diacylglycerol cholinephosphotransferase (E.C. 2.7.8.2), (X) acetylalkylgly-
cerol acetylhydrolase (E.C. 3.1.1.71), (Y) 1-alkyl-2-acetylglycerol O-acyltransferase (E.C. 2.3.1.125), (Z) alkylglycerophosphocholine O-acetyltransferase (E.C. 2.3.1.67). METABOLITES
(1) glycerone phosphate (dihydroxyacetone phosphate), (2) 1-acyl-glycerone 3-phosphate, (3) 1-O-alkyl-glycerone 3-phosphate, (4) 1-O-alkyl-sn-glycero-3-phosphate, (5) 1-O-
alkyl-sn-glycerol, (6) 1-O-alkyl-2-acyl-sn-glycero-3-phosphate, (7) 1-O-alkyl-2-acyl-sn-glycerol, (8) 1-O-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine (plasmanylethanolamine),
(9) 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine (plasmanylcholine), (10) 1-O-alk-10-enyl-2-acyl-sn-glycero-3-phosphoethanolamine (plasmenylethanolamine), (11) 1-O-alk-10-
enyl-2-acyl-sn-glycero-3-phosphocholine (plasmenylcholine), (12) 1-O-alkenyl-2-acyl-sn-glycerol, (13) 1-O-alk-10-enyl-sn-glycero-3-phosphocholine (lysoplasmenylcholine), (14)
1-O-alk-10-enyl-sn-glycero-3-phosphoethanolamine (lysoplasmenylethanolamine), (15) fatty aldehyde, (16) sn-glycero-3-phosphocholine, (17) sn-glycero-3-phosphoethanolamine,
(18) 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF), (19) 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF), (20) 1-O-alkyl-sn-glycero-3-phosphoethanolamine, (21) glyc-
erol or sn-glycero-3-phosphocholine or sn-glycero-3-phosphoethanolamine, (22) long-chain fatty acid, (23) 1-O-alkyl-2-acetyl-sn-glycero-3-phosphate, (24) 1-O-alkyl-2-acetyl-sn-
glycerol, (25) 1-O-alkyl-sn-glycerol, (26) 1-O-alkyl-2-acetyl-3-acyl-sn-glycerol.
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renal, neuronal, pulmonary, immunological disorders and in shock
[23] and was ﬁrst described in 1972 [24]. PAF is synthesised by two
alternative strategies in the body, the de novo and the remodelling
pathway. For its role as mediator, the remodelling pathway is of
prime importance. This pathway includes cleavage of a precursor
lipid by phospholipase A2, acetylation at the sn-2 position to yield
its active form, and deacetylation at the sn-2 position to inactivate
the molecule (reactions (A2), (Z) and (O)), respectively, Fig. 1, [25].
Plasmalogens, a subclass of ether phospholipids which harbours
a vinyl double bond in the alkyl side chain ((10) and (11) in Fig. 1),
are found ubiquitously in animal cells and form 18% of the total
phospholipid mass in humans [26]. The sn-2 position of glycerol in
plasmalogens is very commonly acylated by poly-unsaturated fatty
acids of the omega-3 and omega-6 class (e.g. arachidonic acid) [4],
the sn-3 position carries either a phosphocholine or a phosphoe-
thanolamine residue. Plasmalogens seem to have implications in
protection against oxidative stress, however, their function still
remains somewhat obscure (for review see [27]). Plasmalogen
contents are highest in brain and spermatozoa and lowest in liver
[4]. Another ether lipid species especially enriched in humanspermatozoa is seminolipid, a sulfogalactolipid (for review see
[28]).
Ether lipids are a constituent of glycosylphosphatidylinositol
(GPI) anchors which link proteins to membranes via post-
translational modiﬁcation. GPI anchor synthesis has been shown to
be indispensable for the germline development of the nematode
Caenorhabditis elegance [29]. The lipid part of GPI anchors is
frequently 1-O-alkyl-2-acyl-sn-glycerol.
1.2. Ether lipid metabolism
The biosynthetic routes to ether lipids including plasmalogens
involve many integral membrane enzymes not all of which have
been characterised in detail. However, most enzymatic steps are
known. A short overview of the central part of ether lipid metab-
olism is given in Fig. 1, the respective enzyme names and their E.C.
numbers can be found in Table 1. For more detailed information the
reader is referred to a recent review [30].
The ﬁrst step in ether lipid synthesis is catalysed by glycerone-
phosphate O-acyltransferase (E.C. 2.3.1.42) (A), a peroxisomal
enzyme that acylates glycerone phosphate (dihydroxyacetone
Table 1
Overview of enzymes shown in Fig. 1. All enzymes are listed according to their letter
code used in Fig.1 together with their full name and E.C. number. Enzymes described
in Sections 2.1. and 2.2. are listed with the respective references mentioned in the
main text.
Letter Full name E.C. number Reference
(A) Glycerone-phosphate O-acyltransferase 2.3.1.42
(A2) Phospholipase A2 3.1.1.4
(B) Alkylglycerone-phosphate synthase 2.5.1.26
(C) Acylglycerone-phosphate reductase 1.1.1.101
(D) Alkylglycerol kinase 2.7.1.93 [50]
(E) Alkylglycerolphosphate 2-O-acyltransferase 2.3.1.-
(F) Phosphatidate phosphatase 3.1.3.4
(G) Ethanolamine-phosphotransferase 2.7.8.1
(H) Diacylglycerol cholinephosphotransferase 2.7.8.2
(I) Plasmanylethanolamine desaturase 1.14.99.19 [39,52]
(J) Transferase 2.6.-.-
(K) Phospholipase C 3.1.4.3
(L) 1-Alkylglycerophosphocholine
O-acyltransferase
2.7.8.22 [59]
(M) Alkenylglycerophosphocholine hydrolase 3.3.2.2 [33,42]
(N) Alkenylglycerophosphoethanolamine
hydrolase
3.3.2.5 [42,55]
(O) 1-O-Alkyl-2-acetylglycerophosphocholine
esterase
3.1.1.47
(P) Alkylglycerol monooxygenase 1.14.16.5 [43e47]
(Q) Long-chain-aldehyde dehydrogenase 1.2.1.48
(R) 1-Alkenylglycerophosphocholine
O-acyltransferase
2.3.1.104 [56]
(S) 1-Alkylglycerophosphocholine
O-acyltransferase
2.3.1.63 [49,57]
(T) 1-Alkenylglycerophosphoethanolamine
O-acyltransferase
2.3.1.121 [57,58]
(U) Alkylglycerophosphate 2-O-acetyltransferase 2.3.1.105 [53]
(V) Alkylacetylglycerophosphatase 3.1.3.59 [53,54]
(W) Diacylglycerol cholinephosphotransferase 2.7.8.2
(X) Acetylalkylglycerol acetylhydrolase 3.1.1.71 [48]
(Y) 1-Alkyl-2-acetylglycerol O-acyltransferase 2.3.1.125 [60]
(Z) Alkylglycerophosphocholine
O-acetyltransferase
2.3.1.67 [49,53]
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of the resulting 1-acyl-glycerone 3-phosphate (2) is then
substituted by a fatty alcohol yielding 1-O-alkyl-glycerone
3-phosphate (3) in a complex reaction catalysed by alkylglycerone-
phosphate synthase (E.C. 2.5.1.26) (B) [31]. This peroxisomal
enzyme uses FAD as cofactor.
The ﬁrst glycerol based intermediate 1-O-alkyl-sn-glycero-3-
phosphate (4) is obtained by acylglycerone-phosphate reductase
(E.C. 1.1.1.101) (C) by reduction of the keto group at C2 at the
expense of one molecule NADPH. 1-O-Alkyl-sn-glycero-3-
phosphate (4) is an important branching point in ether lipid
synthesis either being the starting point for PAF biosynthesis or for
all plasmanyl/plasmenyl species. According to a widely used
nomenclature, ether phospholipids without a vinyl double bond are
termed plasmanyl species (e.g. 1-O-alkyl-2-acyl-sn-glycero-3-
phosphoethanolamine (8), is termed plasmanylethanolamine),
whereas ether phospholipids with the vinyl double bond are called
plasmenyl species (e.g. 1-O-alk-10-enyl-2-acyl-sn-glycero-3-
phosphoethanolamine (10), a plasmalogen, is termed plasmenyle-
thanolamine). 1-O-Alkyl-sn-glycero-3-phosphate (4) can also be
generated in the body by alkylglycerol kinase (E.C. 2.7.1.93) (D),
a microsomal enzyme that phosphorylates dietary alkylglycerols
(5) with ATP.
1-O-Alkyl-sn-glycero-3-phosphate (4) is transported to the
endoplasmic reticulum [32] and is esteriﬁedwith acyl-CoA at the sn-
2 position of glycerol by a not further characterised acyltransferase,
i.e. alkylglycerolphosphate 2-O-acyltransferase (E.C. 2.3.1.-) (E)
yielding 1-O-alkyl-2-acyl-sn-glycero-3-phosphate (6), the phos-
phate of which is removed by phosphatidate phosphatase (E.C.3.1.3.4) (F). The resulting 1-O-alkyl-2-acyl-sn-glycerol (7) can
then either be converted to 1-O-alkyl-2-acyl-sn-glycero-3-
phosphoethanolamine (plasmanylethanolamine (8)) with cytidine-
diphosphate-ethanolamine via ethanolamine-phosphotransferase
(E.C. 2.7.8.1) (G) or to 1-O-alkyl-2-acyl-sn-glycero-3-
phosphocholine (plasmanylcholine (9)) by diacylglycerol chol-
inephosphotransferase (E.C. 2.7.8.2) (H). The plasmanylethanol-
amine (8) is oxidised by plasmanylethanolamine desaturase (E.C.
1.14.99.19) (I) to yield the vinyl double bond in plasmenylethanol-
amine (1-O-alk-10-enyl-2-acyl-sn-glycero-3-phosphoethanolamine
(10), a plasmalogen) in a reaction involving cytochrome b5 reduc-
tase, molecular oxygen and a reduction equivalent. Plasmanylcho-
lines (9) are no substrates for plasmanylethanolamine desaturase (I).
Plasmenylcholines ((11), 1-O-alk-10-enyl-2-acyl-sn-glycero-3-
phosphocholines) therefore are produced from plasmenylethanol-
amines (10), possibly by a not further characterised transferase (E.C.
2.6.-.-) (J). Alternatively, plasmenylethanolamines (10) are cleavedby
phospholipase C (E.C. 3.1.4.3) (K) to 1-O-alkenyl-2-acyl-sn-glycerol
(12) and then transformed to plasmenylcholine (11) by
1-alkylglycerophosphocholine O-acyltransferase (E.C. 2.7.8.22) (L).
Phospholipase A2 (E.C. 3.1.1.4) (A2) hydrolyses the ester bond at sn-2
of plasmenylcholines (11) to the resulting 1-O-alk-10-enyl-sn-glyc-
ero-3-phosphocholine (lysoplasmenylcholines (13)), and similarly,
the ester bond at sn-2 of plasmenylethanolamines (10) to 1-O-alk-10-
enyl-sn-glycero-3-phosphoethanolamine (lysoplasmenylethanol-
amines (14)). Phospholipids with a free hydroxy group at the sn-2
position are known as lysolipids due to their membrane-dissolving
properties. Lysoplasmenylcholines (13) are degraded to fatty alde-
hyde (15) and sn-glycero-3-phosphocholine (16) by alkenylglycer-
ophosphocholine hydrolase (E.C. 3.3.2.2) (M) [33]. Likewise,
lysoplasmenylethanolamines (14) are degraded to fatty aldehyde
(15) and sn-glycero-3-phosphoethanolamine (17) by alkenylglycer-
ophosphoethanolamine hydrolase (E.C. 3.3.2.5) (N).
Deacetylation at the sn-2 glycerol position of 1-O-alkyl-2-acetyl-
sn-glycero-3-phosphocholine (platelet-activating factor, PAF, (18))
by a speciﬁc acetylhydrolase (1-O-alkyl-2-acetylglyce
rophosphocholine esterase (E.C. 3.1.1.47) (O)), and deacylation of
plasmanylcholines (9) or plasmanylethanolamines (8) by phos-
pholipases A2 (E.C. 3.1.1.4) (A2) leads to production of 1-O-alkyl-2-
lysoglycerols ((19) and (20)), the ether bond of which is cleaved in
a tetrahydrobiopterin-dependent manner by alkylglycerol mono-
oxygenase (E.C. 1.14.16.5) (P) yielding the corresponding glycerol
derivatives (21) and again a long-chain fatty aldehyde (15) which is
further oxidised by long-chain-aldehyde dehydrogenase (E.C.
1.2.1.48) (Q) in an NAD-dependent manner to the long-chain
fatty acid (22). As an alternative to degradation, lysolipids may
be acylated back by speciﬁc acyltransferases. Such reactions in Fig.1
are, in addition to the reaction (E) mentioned above,
1-alkenylglycerophosphocholine O-acyltransferase (E.C. 2.3.1.104)
(R), 1-alkylglycerophosphocholine O-acyltransferase (E.C. 2.3.1.63)
(S) and 1-alkenylglycerophosphoethanolamine O-acyltransferase
(E.C. 2.3.1.121) (T).
The PAF de novo pathway starts at the important branching
point 1-O-alkyl-sn-glycero-3-phosphate (4) where alkylglycer-
ophosphate 2-O-acetyltransferase (E.C. 2.3.1.105) (U) acetylates at
the sn-2 hydroxy group yielding 1-O-alkyl-2-acetyl-sn-glycero-3-
phosphate (23). Alkylacetylglycerophosphatase (E.C. 3.1.3.59) (V)
removes the phosphate to generate 1-O-alkyl-2-acetyl-sn-glycerol
(24). The last step in PAF de novo synthesis is catalysed by diac-
ylglycerol cholinephosphotransferase (E.C. 2.7.8.2) (W) which
transfers a phosphocholine residue to the sn-3 position. 1-O-Alkyl-
2-acetyl-sn-glycerol (24), the PAF precursor, can be deacetylated to
1-O-alkyl-sn-glycerol (25) in a similar reaction like PAF itself
(reaction (O)) by acetylalkylglycerol acetylhydrolase (E.C. 3.1.1.71)
(X). The resulting 1-O-alkyl-sn-glycerols (25) are identical in their
K. Watschinger, E.R. Werner / Biochimie 95 (2013) 59e6562chemical structure with the dietary alkylglycerols (5) mentioned
above, and are substrates of alkylglycerol monooxygenase (P).
Another detour from the last step of PAF synthesis is the acylation
of 1-O-alkyl-2-acetyl-sn-glycerol (24) at the sn-3 position with
1-alkyl-2-acetylglycerol O-acyltransferase (E.C. 2.3.1.125) (Y) to
yield 1-O-alkyl-2-acetyl-3-acyl-sn-glycerol (26).
A more important route to PAF, however, is the remodelling
pathway which in a ﬁrst step consists in deacylation of the acyl
residue, predominantly arachidonate, at the sn-2 position of 1-O-
alkyl-2-acyl-sn-glycero-3-phosphocholine (9) to yield 1-O-alkyl-
sn-glycero-3-phosphocholine (lyso-PAF, (19)) by a phospholipase
A2 (A2). Acetylation of lyso-PAF (19) with acetyl-CoA by alkylgly-
cerophosphocholine O-acetyltransferase (E.C. 2.3.1.67) (Z) then
yields PAF (18) in this remodelling pathway. Deactivation of PAF is
mostly accomplished by 1-O-alkyl-2-acetylglycerophosphocholine
esterase (O) as mentioned above.
1.3. Ether lipid deﬁciency
Deﬁciencies in ether lipids are most commonly caused by
defects in peroxisomal assembly (e.g. Zellweger syndrome, rhizo-
melic chondrodysplasia punctata) because the ﬁrst two biosyn-
thetic enzymes, glycerone-phosphate O-acyltransferase (A) and
alkylglycerone-phosphate synthase (B) are localised to these
organelles. A good tool to study such a deﬁciency is a mouse model.
Indeed, two models are available to date which have deletions in
one of the ﬁrst two enzymes of ether lipid synthesis and therefore
completely lack ether lipids.
Knockouts in glycerone-phosphate O-acyltransferase (dihy-
droxyacetone phosphate acyltransferase, DHAPAT, E.C. 2.3.1.42) (A)
display hypomyelination of central nerves, structural alterations in
testis accompanied by male infertility and early postnatal bilateral
cataractogenesis due to impaired lens organisation leading to
blindness of aged animals [34e36]. Isolated nerve terminals from
ether lipid deﬁcient mice showed impaired neurotransmission,
reduced respiration and a lowered ATP/ADP ratio. Although ether
lipid deﬁcient tissue contains less lipid peroxidation products,
ﬁbroblasts lacking ether lipids are more susceptible to oxidative
stress [37]. Blind sterile 2 mice were shown to have a mutation in
alkylglycerone-phosphate synthase (AGPS, E.C. 2.5.1.26) (B). These
mice also have a very similar phenotype with reduced ether lipid
quantities, male infertility due to absence of mature sperm and
a severely affected lens causing cataract and blindness [38].
Another possibility to study ether lipid function is ether lipid
deﬁcient cell lines. These were either isolated from patients with
inherited metabolic diseases in ether lipid biosynthetic enzymes or
have been generated by random mutagenesis and sophisticated
clone selection techniques [4]. By this a murine macrophage cell
line with a combined defect in enzymes (A) and (I) could be
generated [39]. Investigations in these cells showed that ether lipid
levels can be selectively restored by using different metabolic
precursors and that the plasmalogen vinyl double bond is impor-
tant for protection against oxidants [40].
2. Orphan enzymes in ether lipid metabolism
Orphan proteins have known functions but no corresponding
sequence. The ORENZA database (a database of ORphan ENZyme
Activities, http://www.orenza.u-psud.fr [41]) keeps an actual list of
all orphan enzymes. These enzymes have well deﬁned reaction
characteristics described by an Enzyme Commission number (E.C.)
but no sequence information has been made available for them. To
date there are 1187 orphan enzymes listed in ORENZA (version
2_34 of 03-May-2011), 384 of these are associated to enzymes
integrated in the Kyoto Encyclopedia of Genes and Genomes(KEGG) database. Twelve ORENZA orphan enzymes are members of
the KEGG ether lipid metabolism pathway (KEGG release 61.1,
February 1, 2012).
Due to the lipophilic nature of the substrates, many enzymes
involved in the ether lipid biosynthetic pathway are integral
membrane enzymes. These enzymes are often especially sensitive
towards biochemical puriﬁcation protocols and need strictly opti-
mised solubilisation conditions to retain activity. For some of these
enzymes puriﬁcation in active form has never been achieved. This
explains the difﬁculty in assigning a sequence to some of these
enzymes. The following Section 2.1. describes four enzymes of ether
lipidmetabolismwith recently assigned sequence (grey circles with
white lettering in Fig.1). Themethods applied to ﬁnd the sequences
of these four enzymes will be brieﬂy mentioned. Section 2.2. will
then describe enzymes in ether lipid metabolism with unknown
sequence (black circles with white lettering in Fig. 1). This includes
e.g. plasmanylethanolamine desaturase (I), the key enzyme for the
synthesis of one of the most abundant lipid classes in our body, the
plasmalogens.
2.1. Enzymes in ether lipid metabolism with recently assigned
sequence
Alkenylglycerophosphocholine hydrolase (lysoplasmaloge-
nase (E.C. 3.3.2.2) (M)) catalyses cleavage of the vinyl ether bond of
lysoplasmenylcholines (13) yielding a fatty aldehyde (15) and the
glycerol derivative (16). This enzyme, though still reported as
orphan enzyme in ORENZA, has recently been cloned and charac-
terised by Wu and co-workers [42]. They succeeded in 500-fold
puriﬁcation of alkenylglycerophosphocholine hydrolase from rat
liver microsomes after solubilisation with 2% octyl glucoside and
four chromatographical steps. The enriched protein had a protein
mass of 19 kDa on an SDS gel. The band was excised and the
sequence determined by mass spectrometry. The identiﬁed
peptides corresponded to TMEM86b, a protein with previously
unknown function. Identity was conﬁrmed by transfection of tag-
ged protein into mammalian cells and Escherichia coli and testing of
activity using an alkenylglycerophosphocholine hydrolase assay
and quantiﬁcation of protein expression by Western blotting
against the epitope tag. Transmembrane prediction tools revealed
that alkenylglycerophosphocholine hydrolase contains six trans-
membrane regions in its 226 amino acid residues. The authors
recombinantly expressed the protein and demonstrated that it also
accepts lysoplasmenylethanolamines (14) as substrates. Thus
TMEM86b displays two enzymatic activities, alkenylglycer-
ophosphocholine hydrolase (E.C. 3.3.2.2) (M) and alkenylglycer-
ophosphoethanolamine hydrolase (E.C. 3.3.2.5) (N) [42]. As
mentioned in Section 2.2. below, a protein associated exclusively
with alkenylglycerophosphoethanolamine hydrolase activity (E.C.
3.3.2.5) (N) but not with alkenylglycerophosphocholine hydrolase
(EC 3.3.2.2) (M) with so far unknown sequence may be additionally
encoded in mammalian genomes.
Alkylglycerol monooxygenase (E.C. 1.14.16.5) (P) is a tetrahy-
drobiopterin-dependent enzyme which cleaves the ether bond of
1-O-alkyl-sn-glycerols (19, 20, 25) via a hydroxylation and subse-
quent rearrangement of the resulting hemiacetal into a fatty alde-
hyde (15) and a glycerol derivative (21). It accepts alkylglycerols
which are unsubstituted at sn-3 or which carry a wide range of
common phospholipid substitutions at sn-3, except the phosphate
group alone as in (4), which is no substrate of the enzyme [43]. The
enzyme requires, however, a free hydroxy group at sn-2 and cannot
cleave lipids which carry a vinyl ether bond. Thus, only lysoalkyl-
glycerols and lysoalkylglycerol phospholipids are substrates.
Alkylglycerol monooxygenase was ﬁrst described already in 1964
by Tietz and co-workers [44] but only little advance has been made
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were able to assign a sequence to this enzyme by bioinformatic
selection of candidate clones, transfection into mammalian cells
and screening for enzymatic activity [45]. An important prerequi-
site for this was a reliable and very sensitive assay for alkylglycerol
monooxygenase which uses a ﬂuorescent alkylglycerol as substrate
and subsequent HPLC separation with ﬂuorescence detection [46].
The assigned sequence, a protein with unknown function formerly
named TMEM195, belongs to the family of fatty acid hydroxylases,
a protein class of hydroxylases and desaturases which contain a di-
iron centre for catalysis and are extremely labile towards puriﬁca-
tion protocols. No member of this enzyme family has ever been
puriﬁed to homogeneity. Alkylglycerol monooxygenase is located
in the membrane of endoplasmic reticulum. Upon analysis of its
primary sequence using prediction tools, nine transmembrane
domains were identiﬁed in its 445 amino acid residues [47].
Acetylalkylglycerol acetylhydrolase (alkylacetylglycerol ace-
tylhydrolase (E.C. 3.1.1.71) (X)) is responsible for hydrolysis of the
acetyl moiety of 1-O-alkyl-2-acetyl-sn-glycerol (24), the direct
precursor of PAF in the de novo pathway. In 2006, the predicted
protein KIAA1363 was identiﬁed as gene coding for this enzymatic
activity by using a multidimensional proﬁling strategy [48]. The
authors had previously found high expression of KIAA1363 in
cancer cell lines. By taking advantage of a speciﬁc inhibitor against
the enzyme they were able to detect a signiﬁcantly downregulated
metabolite in inhibitor-treated cell lines by liquid
chromatographyemass spectrometry. This metabolite was then
identiﬁed to be 1-O-hexadecylglycerol. From the information of
equal regulation in enzyme activity and metabolite quantities, it
could be concluded that 1-O-hexadecylglycerol was the product of
the reaction. To test whether the substrate consisted of the 2-
acetylated form of 1-O-hexadecylglycerol, mammalian cells were
transfected with KIAA1363 and checked for acetylalkylglycerol
acetylhydrolase activity which was indeed strongly elevated above
background.
Alkylglycerophosphocholine O-acetyltransferase (lyso-PAF
acetyltransferase (E.C. 2.3.1.67) (Z)), the sequence of which was
termed LPCAT2 and published in 2006, is the PAF biosynthetic
enzyme in the remodelling pathway and is induced by the
inﬂammatory stimulus lipopolysaccharide [49]. Interestingly, this
enzyme also displays a lysophosphatidylcholine acyltransferase
activity because under resting conditions in a cell it is able to
transfer an arachidonoyl moiety to glycerophospholipids, thereby
synthesising a PAF precursor. Assignment of the gene coding for
this enzyme has been achieved by expression of a putative open
reading frame with sequence homology to another previously re-
ported lysophosphatidylcholine transferase and subsequent anal-
ysis of its tissue and subcellular localisation, substrate speciﬁcity
and identity of the product [49].
2.2. Enzymes in ether lipid metabolism without known sequence
(orphans)
Alkylglycerol kinase (ATP:alkylglycerol phosphotransferase
(E.C. 2.7.1.93) (D)) is a microsomal enzyme that uses 1-O-alkyl-sn-
glycerols (5) as substrates and phosphorylates them to 1-O-alkyl-
sn-glycero-3-phosphate (4) which is an important branch point in
ether lipid metabolism [50]. This enzyme is responsible for the use
of dietary supplements such as (5) in order to bypass the ﬁrst two,
peroxisomally located, reactions of the de novo ether lipid biosyn-
thesis (A) and (B) [51]. So far no sequence of this enzyme has been
described.
Plasmanylethanolamine desaturase (D10-alkyl desaturase
(E.C. 1.14.99.19) (I)) is the enzyme that converts plasmanyletha-
nolamine (8) into plasmenylethanolamine (a plasmalogen, (10)) byintroduction of the vinyl double bond. This desaturase is
membrane-bound and requires cytochrome b5, molecular oxygen
and either NADPH or NADH as cofactors for functional catalysis
[52]. If this enzyme is disrupted, no ether lipids with a vinyl double
bond (i.e. no plasmalogens) can be formed in the cell [39]. Sequence
information for plasmanylethanolamine desaturase is still missing.
Alkylglycerophosphate 2-O-acetyltransferase (acetyl-
CoA:alkyl-lysoglycerophosphate acetyltransferase (E.C. 2.3.1.105)
(U)) is a microsomal enzyme which has been shown to have
a different substrate speciﬁcity than alkylglycerophosphocholine
O-acetyltransferase (E.C. 2.3.1.67) (Z) [53]. This enzyme is expressed
in signiﬁcant amounts in spleen, but also brain, heart, lung and liver
[53]. No sequence has been reported to date.
Alkylacetylglycerophosphatase (alkylacetylglycerophosphate
phosphohydrolase (E.C. 3.1.3.59) (V)) is responsible together with
alkylglycerophosphate 2-O-acetyltransferase (U) for formation of
1-O-alkyl-2-acetyl-sn-glycerol (24), the direct precursor of PAF in
the de novo pathway. This enzyme is also found in the microsomal
fraction and is inhibited by reduced assay temperature (23 C),
sodium vanadate and sodium ﬂuoride [53]. A detailed character-
isation of this orphan enzyme is still missing, however, Lee and co-
workers have shown that it is predominantly expressed in kidney
medulla. Smaller amounts of activity were found in brain, spleen,
kidney cortex and lung [54]. This enzyme accepts both carbon chain
lengths of 16 and 18 atoms at the sn-1 position at glycerol, the sn-2
position must be acetylated [54]. Its sequence is still unknown.
Alkenylglycerophosphoethanolamine hydrolase (E.C. 3.3.2.5)
(N): As mentioned above, ORENZA version 2_34 lists twelve orphan
enzymes in the KEGG pathway of ether lipid metabolism. In the last
year, however, alkenylglycerophosphocholine hydrolase (lyso-
plasmalogenase (E.C. 3.3.2.2) (M)), has been identiﬁed to be enco-
ded by TMEM86b ([42], see Section 2.1. above). The recombinant
protein cleaves both lysoplasmenylcholine (13) and lysoplasmeny-
lethanolamine (14), thus displays alkenylglycerophosphocholine
hydrolase (EC 3.3.2.2) (M) and alkenylglycerophosphoethanolamine
hydrolase (E.C. 3.3.2.5) (N) enzymatic activity. Biochemical evidence
suggests the occurrence of an additional speciﬁc alkenylglycer-
ophosphoethanolamine hydrolase (E.C. 3.3.2.5) (N) which cleaves
lysoplasmenylethanolamine (14) but not lysoplasmenylcholine (13)
[55]. So far no sequence for this enzyme has been found.
1-Alkenylglycerophosphocholine O-acyltransferase (E.C.
2.3.1.104) (R) reacylates lysoplasmenylcholine (13) to plasme-
nylcholine (11). The activity of this enzyme is high e.g. in human
erythrocytes, which contain a considerable amount of plasmal-
ogens [56]. An identical reaction is also described as plasmalogen
synthase (E.C. 2.3.1.25), an additional orphan enzyme. No
sequences corresponding to these two E.C. numbers have been
described yet.
1-Alkylglycerophosphocholine O-acyltransferase (lyso-PAF
acyltransferase, E.C. 2.3.1.63) (S) reacylates lysoplasmanylcholine
(19), which is also termed lyso-PAF. The protein encoded by the
gene identiﬁed for lyso-PAF acetyltransferase (Z), LPCAT2, does also
accept acyl-CoA in addition to acetyl-CoA as co-substrate. Thus it
exhibits 1-alkylglycerophosphocholine O-acyltransferase (S)
activity [49]. Surprisingly, however, the inﬂammatory stimulant
lipopolysaccharide augmented only lyso-PAF acetyltransferase (Z)
but not lyso-PAF acyltransferase (S) activity [49]. Thus, although the
LPCAT2 gene product also displays 1-alkylglycerophosphocholine
O-acyltransferase (S) activity in vitro, it remains open whether
this is the gene responsible for this activity inside the cells. In
addition, a novel mammalian brain isoform of acyl-CoA-
lysophospholipid acyltransferase, LPEAT2, has been described
which also displayed 1-alkylglycerophosphocholine O-acyl-
transferase (S) activity [57]. Further work is needed to unequivo-
cally assign a sequence to this enzymatic activity.
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(E.C. 2.3.1.121) (T) has been shown to occur in guinea pig heart.
Based on acyl speciﬁcities, pH proﬁles and their responses to heat
inactivation and thiol reagents it has been shown that this enzyme
is different from the enzyme acylating the corresponding ester
lipid, i.e. 1-acylglycerophosphoethanolamine acyltransferase [58].
On the other hand, it has been described that the LPEAT2
gene product displays acetyltransferase activity to both, 1-acyl and
1-alkenylglycerophosphoethanolamines [57]. Again it will be
crucial to demonstrate which of the gene products displaying this
activity are responsible for the respective metabolic reaction in the
various tissues.
1-Alkylglycerophosphocholine O-acyltransferase (E.C.
2.7.8.22) (L) is another orphan enzyme listed in ether lipid
metabolism. In this case biochemical evidence indicates that this
enzyme may be similar to diacylglycerol cholinephosphotransfer-
ase (E.C. 2.7.8.2) (H) [59].
1-Alkyl-2-acetylglycerol O-acyltransferase (E.C. 2.3.1.125)
(Y) is an enzyme acylating the hydroxy group at sn-3 of glycerol in
1-O-alkyl-2-acetyl-sn-glycerol (24) to form 1-O-alkyl-2-acetyl-3-
acyl-sn-glycerol (26). This enzyme has been observed in HL-60
promyelocytic leukaemia cells and was shown to differ bio-
chemically from diacylglycerolO-acyltransferase (E.C. 2.3.1.20) [60].
Taken together, many enzymes important in ether lipid
metabolism still lack an equivocal annotation to a gene responsible
for the corresponding metabolic activity inside the cells. Recent
sequence assignments of ether lipid metabolising enzymes had
been achieved only in one case, i.e. alkenylglycerophosphocholine
hydrolase (M), by classical protein puriﬁcation, sequencing of the
puriﬁed protein and cloning of the gene [42]. In the three further
cases, the protein could not be puriﬁed. Alternative strategies used
were development of a selective inhibitor and multidimensional
metabolic proﬁling in the case of acetylalkylglycerol acetylhy-
drolase (X) [48], bioinformatic candidate gene selection combined
with recombinant expression in cells for alkylglycerol mono-
oxygenase (P) [45] and expression of an open reading frame
homologous to a recently described acyltransferase for alkylgly-
cerophosphocholine O-acetyltransferase (Z) [49]. As indicated in
Section 2.2., several important enzymes still await the assignment
of a sequence. This includes plasmanylethanolamine desaturase (I),
the key enzyme of the biosynthesis of one of the most abundant
phospholipid classes in our body, the plasmalogens.Acknowledgement
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